The point I was making is that $33 as a sale to a company that is considering evaluating Petrozene is a perfectly reasonable interepretation - and is the most probable one.
I was not making any comment on whether Petrozene is desired or not. My position on that has been made before.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.